메뉴 건너뛰기




Volumn 9, Issue 5, 2014, Pages

A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; EXCIPIENT; PYRUVIC ACID; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

EID: 84901609121     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095281     Document Type: Article
Times cited : (29)

References (25)
  • 2
    • 0033577725 scopus 로고    scopus 로고
    • Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936
    • Sum PE, Petersen P (1999) Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 9: 1459-1462.
    • (1999) Bioorg Med Chem Lett , vol.9 , pp. 1459-1462
    • Sum, P.E.1    Petersen, P.2
  • 3
    • 0032918653 scopus 로고    scopus 로고
    • In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)
    • Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT (1999) In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43: 738-744. (Pubitemid 29165733)
    • (1999) Antimicrobial Agents and Chemotherapy , vol.43 , Issue.4 , pp. 738-744
    • Petersen, P.J.1    Jacobus, N.V.2    Weiss, W.J.3    Sum, P.E.4    Testa, R.T.5
  • 4
    • 34547464547 scopus 로고    scopus 로고
    • Wyeth Pharmaceuticals Inc. Available online: (Accessed 8 July 2013)
    • Wyeth Pharmaceuticals Inc. 2012) Tygacil: Full Prescribing Information. Available online: http://labeling.pfizer.com/showlabeling.aspx?id=491 (Accessed 8 July 2013).
    • (2012) Tygacil: Full Prescribing Information
  • 5
    • 80054762740 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic evaluation of tigecycline
    • Giamarellou H, Poulakou G (2011) Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol 7: 1459-1470.
    • (2011) Expert Opin Drug Metab Toxicol , vol.7 , pp. 1459-1470
    • Giamarellou, H.1    Poulakou, G.2
  • 6
    • 81255192118 scopus 로고    scopus 로고
    • Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia
    • Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, et al. (2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20: 674-688.
    • (2011) Cancer Cell , vol.20 , pp. 674-688
    • Skrtic, M.1    Sriskanthadevan, S.2    Jhas, B.3    Gebbia, M.4    Wang, X.5
  • 7
    • 3042810717 scopus 로고    scopus 로고
    • 2+ cleavage of 16S rRNA
    • DOI 10.1093/jac/dkh125
    • Bauer G, Berens C, Projan SJ, Hillen W (2004) Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2 + cleavage of 16S rRNA. J Antimicrob Chemother 53: 592-599. (Pubitemid 38499772)
    • (2004) Journal of Antimicrobial Chemotherapy , vol.53 , Issue.4 , pp. 592-599
    • Bauer, G.1    Berens, C.2    Projan, S.J.3    Hillen, W.4
  • 9
    • 84874605802 scopus 로고    scopus 로고
    • Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis
    • Jenner L, Starosta AL, Terry DS, Mikolajka A, Filonava L, et al. (2013) Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis. Proc Natl Acad Sci U S A 110: 3812-3816.
    • (2013) Proc Natl Acad Sci U S A , vol.110 , pp. 3812-3816
    • Jenner, L.1    Starosta, A.L.2    Terry, D.S.3    Mikolajka, A.4    Filonava, L.5
  • 11
    • 84875143073 scopus 로고    scopus 로고
    • BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells
    • Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, et al. (2013) BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12: 329-341.
    • (2013) Cell Stem Cell , vol.12 , pp. 329-341
    • Lagadinou, E.D.1    Sach, A.2    Callahan, K.3    Rossi, R.M.4    Neering, S.J.5
  • 12
    • 74949089659 scopus 로고    scopus 로고
    • Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction
    • Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, et al. (2010) Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120: 142-156.
    • (2010) J Clin Invest , vol.120 , pp. 142-156
    • Samudio, I.1    Harmancey, R.2    Fiegl, M.3    Kantarjian, H.4    Konopleva, M.5
  • 13
    • 84864081282 scopus 로고    scopus 로고
    • Therapeutic potential of mitochondrial translation inhibition for treatment of acute myeloid leukemia
    • Schimmer AD, Skrtic M (2012) Therapeutic potential of mitochondrial translation inhibition for treatment of acute myeloid leukemia. Expert Rev Hematol 5: 117-119.
    • (2012) Expert Rev Hematol , vol.5 , pp. 117-119
    • Schimmer, A.D.1    Skrtic, M.2
  • 14
    • 84901633005 scopus 로고    scopus 로고
    • Tigecycline compositions and methods of preparation
    • inventors; Wyeth LLC, assignee February 1 United States patent US. 7,879,828
    • Fawzi MB, Zhu T, Shah SM, inventors; Wyeth LLC, assignee (2011 February 1) Tigecycline compositions and methods of preparation. United States patent US. 7,879,828
    • (2011)
    • Fawzi, M.B.1    Zhu, T.2    Shah, S.M.3
  • 15
    • 24144445122 scopus 로고    scopus 로고
    • Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method
    • DOI 10.1128/AAC.49.9.3903-3909.2005
    • Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, et al. (2005) Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 49: 3903-3909. (Pubitemid 41233048)
    • (2005) Antimicrobial Agents and Chemotherapy , vol.49 , Issue.9 , pp. 3903-3909
    • Bradford, P.A.1    Petersen, P.J.2    Young, M.3    Jones, C.H.4    Tischler, M.5    O'Connell, J.6
  • 18
    • 39449086721 scopus 로고    scopus 로고
    • Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances
    • DOI 10.1038/nprot.2007.521, PII NPROT.2007.521
    • Wiegand I, Hilpert K, Hancock RE (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3: 163-175. (Pubitemid 351266501)
    • (2008) Nature Protocols , vol.3 , Issue.2 , pp. 163-175
    • Wiegand, I.1    Hilpert, K.2    Hancock, R.E.W.3
  • 19
    • 0024599410 scopus 로고
    • Expression of a retinoic acid receptor gene in myeloid leukemia cells
    • Wang C, Curtis JE, Minden MD, McCulloch EA (1989) Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 3: 264-269. (Pubitemid 19092758)
    • (1989) Leukemia , vol.3 , Issue.4 , pp. 264-269
    • Wang, C.1    Curtis, J.E.2    Minden, M.D.3    McCulloch, E.A.4
  • 20
    • 27144477007 scopus 로고    scopus 로고
    • Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells
    • DOI 10.1038/sj.leu.2403917, PII 2403917
    • Warner JK, Wang JC, Takenaka K, Doulatov S, McKenzie JL, et al. (2005) Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia 19: 1794-1805. (Pubitemid 41486158)
    • (2005) Leukemia , vol.19 , Issue.10 , pp. 1794-1805
    • Warner, J.K.1    Wang, J.C.Y.2    Takenaka, K.3    Doulatov, S.4    McKenzie, J.L.5    Harrington, L.6    Dick, J.E.7
  • 21
    • 33644539489 scopus 로고    scopus 로고
    • Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors
    • Schimmer AD, Thomas MP, Hurren R, Gronda M, Pellecchia M, et al. (2006) Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res 66: 2367-2375.
    • (2006) Cancer Res , vol.66 , pp. 2367-2375
    • Schimmer, A.D.1    Thomas, M.P.2    Hurren, R.3    Gronda, M.4    Pellecchia, M.5
  • 22
    • 34347236921 scopus 로고    scopus 로고
    • Organelle isolation: Functional mitochondria from mouse liver, muscle and cultured fibroblasts
    • Frezza C, Cipolat S, Scorrano L (2007) Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nature Protocols 2: 287.
    • (2007) Nature Protocols , vol.2 , pp. 287
    • Frezza, C.1    Cipolat, S.2    Scorrano, L.3
  • 23
    • 84855858726 scopus 로고    scopus 로고
    • Ascorbic acid: An old player with a broad impact on body physiology including oxidative stress suppression and immunomodulation: A review
    • Pohanka M, Pejchal J, Snopkova S, Havlickova K, Karasova JZ, et al. (2012) Ascorbic acid: an old player with a broad impact on body physiology including oxidative stress suppression and immunomodulation: a review. Mini Rev Med Chem 12: 35-43.
    • (2012) Mini Rev Med Chem , vol.12 , pp. 35-43
    • Pohanka, M.1    Pejchal, J.2    Snopkova, S.3    Havlickova, K.4    Karasova, J.Z.5
  • 24
    • 79955643881 scopus 로고    scopus 로고
    • Stable parenteral formulations of tigecycline
    • inventors; Ranbaxy Laboratories Ltd., assignee November 5 United States patent application US. 12/434,499. Publication number US 2009/02756660 A1
    • Chauhan B, Arora VK, Srivastava J, inventors; Ranbaxy Laboratories Ltd., assignee (2009 November 5) Stable parenteral formulations of tigecycline. United States patent application US. 12/434,499. Publication number US 2009/02756660 A1
    • (2009)
    • Chauhan, B.1    Arora, V.K.2    Srivastava, J.3
  • 25
    • 24144487712 scopus 로고    scopus 로고
    • Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent Oxyrase on in vitro activities of tigecycline against recent clinical isolates
    • DOI 10.1128/AAC.49.9.3910-3918.2005
    • Petersen PJ, Bradford PA (2005) Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother 49: 3910-3918. (Pubitemid 41233049)
    • (2005) Antimicrobial Agents and Chemotherapy , vol.49 , Issue.9 , pp. 3910-3918
    • Petersen, P.J.1    Bradford, P.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.